-
1.发明公开COMPOSITIONS AND METHODS FOR UPREGULATING HIPPOCAMPAL PLASTICITY AND HIPPOCAMPUS-DEPENDENT LEARNING AND MEMORY 审中-公开组合物和高度调节的海马可塑性和海马依赖的学习和记忆方法
公开(公告)号：EP3024467A2
公开(公告)日：2016-06-01
申请号：EP14828920.0
申请日：2014-07-23
CPC分类号： A61K9/51 , A61K9/08 , A61K33/00 , A61K45/06 , A61K2300/00
摘要： Provided are methods for enhancing hippocampal plasticity and hippocampal-mediated learning and memory, and/or enhancing the synaptic maturation of neurons, and/or optimizing or enhancing neuronal synaptic transmission, and/or enhancing intracellular oxygen delivery or utilization, and/or enhancing ATP synthesis, comprising administration, to a subject in need thereof of a sufficient amount over a sufficient time, of an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures (e.g., nanobubbles) having an average diameter of less than 100 nm (e.g., in at least one subject group selected from but not limited to normal subjects, subjects recovering from neurological trauma (e.g., accidents or injury to the brain, stroke, oxygen deprivation, drowning, and asphyxia), and subjects with learning disorders (e.g., dyslexia, dyscalculia, dysgraphia, dyspraxia (sensory integration disorder), dysphasia/aphasia, auditory processing disorder, non-verbal learning disorder, visual processing disorder, and attention deficit disorder (ADD)).
-
公开(公告)号：EP2563121A1
公开(公告)日：2013-03-06
申请号：EP11775615.5
申请日：2011-04-29
IPC分类号： A01N39/00
CPC分类号： A61K31/58 , A61K9/0019 , A61K31/522 , A61K31/56 , A61K38/13 , A61K41/0004 , A61K45/06 , A61K2300/00
摘要： Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin is afforded. In certain aspects, protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded, and/or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons is afforded. Preferably, administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent. Additionally provided are methods for preserving or improving motor coordination in a subject having a neurodegenerative condition or disease, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for preserving or improving motor coordination in the subject.
-
公开(公告)号：EP2086668B1
公开(公告)日：2016-11-16
申请号：EP07854427.7
申请日：2007-10-25
CPC分类号： B01F5/0665 , A23L2/54 , A61J3/00 , A61K9/08 , A61K9/10 , A61K33/00 , B01F3/04099 , B01F3/04531 , B01F3/0807 , B01F3/0853 , B01F7/008 , B01F7/00816 , C02F1/727 , C02F3/02 , C09K3/00 , C12M27/00 , Y02W10/15
-
公开(公告)号：EP2207669A1
公开(公告)日：2010-07-21
申请号：EP08842668.9
申请日：2008-10-23
摘要： Particular aspects provide compositions and methods for treating or preventing bacterial infection or at least one symptom related to bacterial infection, and the like in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating bacterial infection or at least one symptom related to bacterial infection is thereby afforded. In particular embodiments, the fluids are gas-enriched fluids or therapeutic compositions and methods, and include oxygen-enriched water optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the gas-enriched therapeutic compositions.
-
5.发明公开COMPOSITIONS AND METHODS FOR INHIBITING AND/OR MODULATING EFFECTOR T-CELLS INVOLVED IN INFLAMMATORY NEURODEGENERATIVE DISEASE 审中-公开组合物和方法在炎症性神经退行性疾病抑制和/或调节效应细胞
公开(公告)号：EP2696849A1
公开(公告)日：2014-02-19
申请号：EP12770569.7
申请日：2012-04-13
发明人： WATSON, Richard L.
CPC分类号： A61K41/0004 , A61K31/56 , A61K31/573 , A61K35/17 , A61K38/07 , A61K38/13 , A61K38/1793 , A61K38/215 , A61K45/06 , A61K2300/00
摘要： Provided are methods for treating inflammatory neurodegenerative diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline; mild cognitive impairment and prion diseases in a mammal), or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and/or modulating the function and/or activity of effector T-cells, and/or for cell-based tolerogenic therapy (e.g., by modulating development and/or function and/or activity of TREG cells and/or dendritic cells (DCs) and/or TH17 cells (e.g., RORγt+ TH17 cells). In certain aspects such methods comprise ex vivo exposure of T-cells and/or APC (e.g., dendridic cells) to at least one electrokinetically-altered fluid as disclosed herein. Combination therapies are additionally provided.
-
公开(公告)号：EP2603199A1
公开(公告)日：2013-06-19
申请号：EP11817151.1
申请日：2011-08-12
IPC分类号： A61K9/00
CPC分类号： A61K33/00 , A61K9/0009 , A61K9/0019 , A61K9/08 , A61K31/58 , A61K33/40 , A61K2300/00
摘要： Provided are methods for treating cardiovascular diseases and related conditions and symptoms (e.g., cardiac arrhythmia, vascular disease, myocardial infarction, congestive heart failure, myocarditis, atherosclerosis, and restenosis), comprising administering to a subject in need thereof a therapeutically effective amount of an electrokinetically altered aqueous fluid as described herein. In particular aspects, the electrokinetically altered aqueous fluids comprise an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures predominantly having an average diameter of less than about 100 nanometers and sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity. Provided are routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions, along with use of the electrokinetically altered aqueous fluids in surgical contexts, including but not limited to cardiovascular related surgeries. Additionally provided are methods for measuring biological activity of electrokinetically altered fluids.
摘要翻译： 所提供的是用于治疗心血管疾病和相关病症和症状（例如心律失常，血管疾病，心肌梗塞，充血性心力衰竭，心肌炎，动脉粥样硬化和再狭窄）的方法，其包括向有需要的受试者施用治疗有效量的 如本文所述的电动改变的含水流体。 在特定方面，电动改变的含水流体包含电荷稳定的含氧纳米结构的离子水溶液，其主要具有小于约100纳米的平均直径并且足以提供对细胞膜电位和细胞膜电导率中的至少一种的调节 。 提供用于电动改变的流体（例如，电动改变的富含气体的流体和溶液）和治疗组合物的施用途径或制剂，以及在手术环境中使用电动改变的水性流体，包括但不限于心血管相关 手术。 另外提供了用于测量电动改变流体的生物活性的方法。
-
7.发明公开
公开(公告)号：EP2097107A2
公开(公告)日：2009-09-09
申请号：EP07854428.5
申请日：2007-10-25
CPC分类号： A61K9/0014 , A61K9/0048 , A61K33/00 , A61K33/14 , A61K45/06 , B01F3/04531 , B01F3/0807 , B01F3/0853 , B01F7/00816 , B29D11/00038 , B29D11/00096 , A61K2300/00
摘要： Particular embodiments disclosed herein relate to gas-enriched fluids, methods of making the same, systems for making the same and/or methods of treatment utilizing the gas-enriched fluids for eye related conditions and/or diseases. In certain embodiments, the gas-enriched fluid is oxygen-enriched water. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids in order to treat a cosmetic and/or therapeutic symptom related to eye conditions and/or diseases.
-
公开(公告)号：EP2603202A1
公开(公告)日：2013-06-19
申请号：EP11817147.9
申请日：2011-08-12
IPC分类号： A61K9/14
CPC分类号： A61K31/136 , A61K31/137 , A61K31/167 , A61K31/436 , A61K31/44 , A61K31/46 , A61K31/47 , A61K31/56 , A61K31/58 , A61K38/13 , A61K38/21 , A61K41/0004 , A61K2300/00
摘要： Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., a taupathy) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for modulating (e.g., decreasing) phosphorylation and/or aggregation of tau protein. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membrane potential and/or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.
-
9.发明公开COMPOSITIONS AND METHODS FOR ENHANCING PHYSIOLOGICAL PERFORMANCE AND RECOVERY TIME 审中-公开组合物和方法改进的运动服务和凝结的恢复时间
公开(公告)号：EP2566460A1
公开(公告)日：2013-03-13
申请号：EP11778466.0
申请日：2011-05-06
IPC分类号： A61K9/14
CPC分类号： A61K33/00 , A23L2/54 , A23L33/10 , A23V2002/00 , A61K9/0053 , A61K9/08 , A61K33/14 , A61K41/0004 , A23V2200/25 , A23V2200/33 , A23V2250/126
摘要： Provided are methods for enhancing exercise (e.g., intense, eccentric, elevated temperature, repetitive, aerobic, and high altitude) performance, comprising administering electrokinetically-altered aqueous fluids comprising an ionic aqueous solution of stably configured charge-stabilized oxygen-containing nanostructures predominantly having an average diameter of less than 100 nanometers. In certain aspects, enhancing exercise performance comprises at least one of: reducing plasma inflammatory cytokines (e.g., IFN-alpha, ENA-78 and BDNF); ameliorating muscle/tendon damage or enhancing muscle/tendon recovery; reducing biomarkers of exercise-induced muscle injury (e.g., CK, plasma myoglobin); ameliorating exercise induced tendinosis, tendonitis, tenosynovitis, avulsion, and tendon strain associated with chronic repetitive movement or enhancing recovering therefrom; increasing VO2 max; decreasing RPE; reducing blood lactate; preserving muscle contractile function (e.g., maximal force, joint ROM); reducing muscle soreness; ameliorating onset of fatigue in an excercising subject. Improved methods for producing electrokinetically altered aqueous fluids (including sports beverages) are also provided.
-
公开(公告)号：EP2214707A1
公开(公告)日：2010-08-11
申请号：EP08841701.9
申请日：2008-10-24
IPC分类号： A61K39/395
CPC分类号： C12N13/00 , A61K31/137 , A61K31/58 , A61K31/7036 , A61K33/00 , A61K33/14 , A61K45/06 , G01N33/6872 , A61K2300/00
摘要： Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.023 秒)
